M icroRNAs (miRNAs) are small ≈22-nucleotide noncoding RNAs that are present from plants to animals and are known to exhibit a wide range of biological activities. There are >700 miRNAs in human, and that accounts for ≈4% of all the expressed transcripts. It is estimated that a single miRNA controls up to a hundred distinctive target genes. It is also estimated that approximately one third of all animal genes are controlled by miRNAs, and thus all the organs are thought to be influenced by miRNAs. 1 The vascular system is not exceptional; miRNA-126, miRNA-218, members of the miRNA17≈92 cluster, and miRNA-10a/10b are reported to be involved in the regulation of endothelial cell (EC) biology, 2-5 whereas miRNA-143/145 is reported to be involved in the regulation of smooth muscle cell biology. 6
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MiRNAs are encoded in the intergenic region, as well as in the exons or introns of various genes. The biogenesis of miRNA from pri-miRNA to premiRNA, miRNA duplex, and finally to mature miRNA is well characterized, but little is known about the mechanisms that regulate the expression of miRNA. Nevertheless, limited analysis of miRNA promoters indicates that miRNA transcription is as complex as that for ordinary genes. The promoter of miRNA seems to be under the control via transcription factors, coactivators, enhancers, repressors, and chromatin modification. 7 In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Kaluza and colleagues provide an important observation showing that the expression of antiangiogenic miR17≈92 cluster in ECs can be modulated by a member of histone deacetylases (HDACs), namely HDAC9. They first showed the proangiogenic activity of HDAC9. HDAC9 silencing reduced EC sprouting and tube formation in culture, impaired angiogenesis in the matrigel plug implanted in mice, and disturbed vascular formation in zebrafish. Moreover, the knockout of HDAC9 gene reduced postnatal retinal vessel formation and blood flow recovery in the mouse model of hindlimb ischemia. Overexpression of wild-type HDAC9 increased the sprouting of ECs in culture, whereas constructs lacking either the nuclear localization sequence or the deacetylation domain did not exhibit such activity. The dependence of nuclear localization and deacetylase activity suggests that HDAC9 transcriptionally controls the angiogenic activity of ECs. They then demonstrated that the proangiogenic activity of HDAC9 was attributable to the repression of miRNA-17≈92 cluster in ECs. The silencing of HDAC9 in ECs increased the expression of miRNA-17≈92 cluster. Furthermore, the inhibition of miRNA-17≈92 cluster rescued the impairment of EC sprouting induced by HDAC9 silencing in culture and partly reversed the defective vascular formation of HDAC9 knockdown in zebrafish.
Epigenetic changes, including histone modification (acetylation/deacetylation), play important role in the expression of various genes. Histone acetylation and deacetylation are balanced by the antagonistic actions of 2 enzyme families, histone acetyltransferases and HDACs. HDACs are classified into 4 classes, and HDAC9 belongs to class II HDACs. Besides histones, a large number of nonhistone proteins can undergo reversible acetylation and deacetylation, and those nonhistone proteins are involved in a wide range of cellular processes, including transcription. 8 Thus, it is not clear at the moment whether or not HDAC9 affects histone deacetylation for the regulation of miR17≈92 cluster expression in ECs. Alternatively, transcription factors, coactivators, or repressors can be the target for the repression of miRNA-17≈92 cluster by HDAC9 in ECs. In addition, HDAC9 may recruit other class of HDACs, which can modulate the expression of miRNA-17≈92 cluster. Apparently, further study is required to clarify the mechanism how HDAC9 represses the miRNA-17≈92 cluster in ECs.
HDAC inhibitors have emerged as a new class of anticancer drugs because of their potent effects on cancers and hematopoietic malignancies. 9 The US Food and Drug Administration has approved 2 HDAC inhibitors, vorinostat and romidepsin, for the treatment of cutaneous T-cell lymphoma. These first generation HDAC inhibitors have pan-HDAC inhibitory profiles. Vorinostat represents a compound with structural features suitable for docking into the HDAC pocket, whereas romidepsin is considered as a prodrug that undergoes reductive metabolism to generate the active intermediate. In addition, >20 chemically different HDAC inhibitors are now in clinical trials for cancer and hematological malignancies. The increasing interest on HDAC inhibitors is related to the efficacy on cancerrelated processes, including angiogenesis. A selective HDAC inhibitor targeting 1 member or 1 class subtype is regarded as less toxic and more tolerable than pan-HDAC inhibitors. 10 As the present study implies that HDCA9 and vascular endothelial growth factor-A are interacting in a positive feedback loop, the specific HDAC9 inhibitor can be considered as a novel option for an antiangiogenic drug. 
